AMGN · Amgen Inc · Financials
$383.12
-8.15 (-2.08%)
At close · Sep 10
Market Cap
$211.53B
Shares
540.63M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$36.75B
+10%
FY2025
Net Income
$7.71B
+88.5%
FY2025
Gross Margin
67.25%
+5.7pp
FY2025
Operating Margin
24.71%
+3pp
FY2025
Diluted EPS
$14.23
+88.2%
FY2025
Operating Cash Flow
$9.96B
-13.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $38.2B – $39.4B | $38.1B | $36.75B | $33.42BG | $28.19B | $26.32B | $25.98BG | $25.42B | $23.36B | $23.75B | $22.85B | $22.99B | $21.66B | $20.06B | $18.68B | $17.27B | $15.58B | $15.05B | $14.64B | $15B | $14.77B | |
| — | $11.61B | $12.04B | $12.86B | $8.45B | $6.41B | $6.45B | $6.16B | $4.36B | $4.1B | $4.07B | $4.16B | $4.23B | $4.42B | $3.35B | $3.2B | $2.71B | — | — | — | — | |
| — | $26.48B | $24.71B | $20.57B | $19.74B | $19.92B | $19.53B | $19.27B | $19.01B | $19.65B | $18.78B | $18.83B | $17.44B | $15.64B | $15.33B | $14.07B | $12.87B | — | — | — | — | |
| — | — | 67.25% | 61.53% | 70.02% | 75.66% | 75.16% | 75.77% | 81.35% | 82.73% | 82.19% | 81.9% | 80.49% | 77.96% | 82.08% | 81.47% | 82.62% | — | — | — | — | |
| — | $7.63B | $7.27B | $5.96B | $4.78B | $4.43B | $4.82B | $4.21B | $4.12B | $3.74B | $3.56B | $3.84B | $4.07B | $4.3B | $4.08B | $3.38B | $3.17B | $2.89B | $2.86B | $3.03B | $3.27B | |
| — | $7.02B | $7.05B | $7.1B | $6.18B | $5.41B | $5.37B | $5.73B | $5.15B | $5.33B | $4.87B | $5.06B | $4.85B | $4.7B | $5.18B | $4.81B | $4.5B | $3.98B | $3.82B | $3.79B | $3.36B | |
| — | $3.79B | $4.3B | $4.8B | $3.2B | $2.6B | $2.6B | $2.8B | $1.4B | $1.3B | $1.3B | $1.5B | $1.4B | $1.4B | $642M | $397M | $380M | $423M | — | — | — | |
| — | $4.9B | $5.17B | $5.59B | $4.07B | $3.42B | $3.4B | $3.6B | $2.21B | $1.95B | $1.96B | $2.11B | $2.11B | $2.09B | $1.29B | $1.09B | $1.06B | $1.02B | $1.05B | $1.07B | $1.2B | |
| — | — | — | — | $267M | — | — | — | — | — | $79M | $19M | $132M | $385M | — | — | — | — | $34M | $92M | — | |
| — | $26.67B | $27.67B | $26.17B | $20.29B | $16.76B | $18.34B | $16.29B | $13.69B | $13.48B | $12.88B | $13.2B | $13.19B | $13.87B | $12.81B | $11.69B | $11.27B | $9.51B | $9.14B | $9.79B | $10.79B | |
| — | $11.43B | $9.08B | $7.26B | $7.9B | $9.57B | $7.64B | $9.14B | $9.67B | $10.26B | $9.97B | $9.79B | $8.47B | $6.19B | $5.87B | $5.58B | $4.31B | $5.55B | $5.51B | $5.21B | $3.98B | |
| — | — | 24.71% | 21.71% | 28.01% | 36.34% | 29.4% | 35.95% | 41.41% | 43.22% | 43.65% | 42.6% | 39.1% | 30.86% | 31.41% | 32.3% | 27.67% | 36.84% | 37.6% | 34.75% | 26.94% | |
| — | $16.32B | $14.25B | $12.85B | $11.97B | $12.98B | $11.04B | $12.74B | $11.88B | $12.21B | $11.93B | $11.9B | $10.58B | $8.28B | $7.15B | $6.67B | $5.37B | $6.56B | $6.56B | $6.29B | $5.18B | |
| — | $422M | $408M | $510M | $1.2B | $127M | $11M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.53B | $2.65B | $506M | $2.83B | -$814M | $259M | $256M | $753M | $674M | $928M | $629M | $603M | $465M | $420M | $485M | $448M | $376M | $276M | $352M | $309M | |
| — | — | — | $10M | -$11M | -$891M | -$33M | -$65M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $10.29B | $8.98B | $4.61B | $7.86B | $7.35B | $6.7B | $8.13B | $9.14B | $9.55B | $9.6B | $9.16B | $7.98B | $5.59B | $5.27B | $5.01B | $4.15B | $5.32B | $5.2B | $5.02B | $3.79B | |
| — | $1.54B | $1.27B | $519M | $1.14B | $794M | $808M | $869M | $1.3B | $1.15B | $7.62B | $1.44B | $1.04B | $427M | $184M | $664M | $467M | $690M | $599M | $963M | $715M | |
| — | $8.74B | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B | $7.72B | $6.94B | $5.16B | $5.08B | $4.35B | $3.68B | $4.63B | $4.61B | $4.05B | $3.08B | |
| — | — | 20.98% | 12.24% | 23.83% | 24.89% | 22.68% | 28.57% | 33.57% | 35.35% | 8.66% | 33.59% | 32.03% | 25.71% | 27.21% | 25.17% | 23.64% | 30.74% | 31.45% | 27.01% | 20.84% | |
| — | $9.17B | $7.52B | $4.31B | $6.66B | $7.12B | $6.08B | $6.81B | $8.08B | $8.31B | $1.77B | $7.73B | $6.47B | $5.31B | $4.77B | $4.32B | $3.7B | $4.74B | $4.53B | $4.12B | $3.12B | |
| USD/shares | — | $16.22 | $14.33 | $7.62 | $12.56 | $12.18 | $10.34 | $12.40 | $12.96 | $12.70 | $2.71 | $10.32 | $9.15 | $6.80 | $6.75 | $5.61 | $4.07 | $4.82 | $4.53 | $3.79 | $2.76 |
| USD/shares | $15.80 – $17.08 | $16.09 | $14.23 | $7.56G | $12.49 | $12.11 | $10.28G | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 | $9.06 | $6.70 | $6.64 | $5.52 | $4.04 | $4.79 | $4.51 | $3.77 | $2.74 |
| shares | — | — | 538M | 537M | 535M | 538M | 570M | 586M | 605M | 661M | 731M | 748M | 758M | 759M | 753M | 775M | 905M | 960M | 1.02B | 1.07B | 1.12B |
| shares | — | — | 542M | 541M | 538M | 541M | 573M | 590M | 609M | 665M | 735M | 754M | 766M | 770M | 765M | 787M | 912M | 965M | 1.02B | 1.08B | 1.12B |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $76.76B in buybacks, $47.14B in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.69×
Peer median 6.48×
EV/EBIT
22.30×
P/E (TTM)
24.32×
Peer median 37.11×
Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $26,419,000,000 | $23,863,000,000 | $19,806,000,000 | $18,595,000,000 | $18,194,000,000 | $18,496,000,000 | $17,224,000,000 | $18,358,000,000 |
| Non Us | $10,332,000,000 | $9,561,000,000 | $8,384,000,000 | $7,728,000,000 | $7,785,000,000 | $6,928,000,000 | $6,138,000,000 | $5,389,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $35,148,000,000 | $32,026,000,000 | $26,910,000,000 | $24,801,000,000 | $24,297,000,000 | $24,240,000,000 | $22,204,000,000 | $22,533,000,000 |
| Other Products | $7,263,000,000 | $5,630,000,000 | $4,696,000,000 | $5,050,000,000 | $5,710,000,000 | $5,374,000,000 | $4,743,000,000 | $5,572,000,000 |
| Prolia | $4,414,000,000 | $4,374,000,000 | $4,048,000,000 | $3,628,000,000 | $3,248,000,000 | $2,763,000,000 | $2,672,000,000 | $2,291,000,000 |
| Repatha | $3,016,000,000 | $2,222,000,000 | $1,635,000,000 | — | — | — | — | — |
| Otezla | $2,265,000,000 | $2,126,000,000 | $2,188,000,000 | $2,288,000,000 | $2,249,000,000 | $2,195,000,000 | $178,000,000 | $0 |
| Enbrel | $2,226,000,000 | $3,316,000,000 | $3,697,000,000 | $4,117,000,000 | $4,465,000,000 | $4,996,000,000 | $5,226,000,000 | $5,014,000,000 |
| EVENITY | $2,100,000,000 | $1,563,000,000 | $1,160,000,000 | $787,000,000 | $530,000,000 | $350,000,000 | — | — |
| Xgeva | $2,084,000,000 | $2,225,000,000 | $2,112,000,000 | $2,014,000,000 | $2,018,000,000 | $1,899,000,000 | $1,935,000,000 | $1,786,000,000 |
| TEPEZZA | $1,903,000,000 | $1,851,000,000 | $448,000,000 | $0 | $0 | — | — | — |
| Product And Service Other | $1,603,000,000 | $1,398,000,000 | $1,280,000,000 | $1,522,000,000 | $1,682,000,000 | $1,184,000,000 | $1,158,000,000 | $1,214,000,000 |
| BLINCYTO | $1,559,000,000 | $1,216,000,000 | $861,000,000 | $583,000,000 | $472,000,000 | — | — | — |
| Nplate | $1,524,000,000 | $1,456,000,000 | $1,477,000,000 | $1,307,000,000 | $1,027,000,000 | $850,000,000 | $795,000,000 | — |
| TEZSPIRE | $1,478,000,000 | $972,000,000 | $567,000,000 | $170,000,000 | — | — | — | — |
| KYPROLIS | $1,412,000,000 | $1,503,000,000 | $1,403,000,000 | $1,247,000,000 | $1,108,000,000 | $1,065,000,000 | $1,044,000,000 | $968,000,000 |
| Aranesp | $1,389,000,000 | $1,342,000,000 | $1,362,000,000 | $1,421,000,000 | $1,480,000,000 | $1,568,000,000 | $1,729,000,000 | $1,877,000,000 |
| KRYSTEXXA | $1,340,000,000 | $1,185,000,000 | $272,000,000 | $0 | $0 | — | — | — |
| Vectibix | $1,175,000,000 | $1,045,000,000 | $984,000,000 | $893,000,000 | $873,000,000 | — | — | — |
| Epogen | — | — | — | — | — | — | $867,000,000 | $1,010,000,000 |
| Neulasta | — | — | — | $1,126,000,000 | $1,734,000,000 | $2,293,000,000 | $3,221,000,000 | $4,475,000,000 |
| Repatha Evolocumab | — | $2,222,000,000 | $1,635,000,000 | $1,296,000,000 | $1,117,000,000 | $887,000,000 | $661,000,000 | $550,000,000 |
| Sensipar Mimpara | — | — | — | — | — | — | $551,000,000 | $1,774,000,000 |
Key facts
CIK
318154
CUSIP
031162100
13F (30d)
1003 filings
954 filers
Visit website
Investor relations